Plaque Modification And Removal Devices Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type

Plaque Modification And Removal Devices Market Summary

Plaque modification and removal devices are used in minimally invasive procedures to treat cardiovascular diseases (CVDs) by removing or modifying arterial plaque, addressing conditions like coronary artery disease (CAD) and peripheral artery disease (PAD). With CVDs causing 17.9 million deaths annually and affecting 20 million CAD and 8.5 million PAD patients in the U.S., the market is driven by rising disease prevalence and an aging population, projected to reach 2.1 billion over 60 by 2050. The shift toward minimally invasive surgeries and technological advancements, such as intravascular lithotripsy (IVL) and AI-assisted imaging, fuel growth. The global market is projected to reach between USD 1.1 billion and USD 2.0 billion in 2025, with a CAGR of 6.0% to 10.0% through 2030.

Regional Analysis
North America: The U.S. leads due to high CVD prevalence and advanced healthcare infrastructure, with Canada focusing on elderly care.
Europe: Germany, France, and the UK drive demand with robust cardiovascular care systems.
Asia Pacific: China and India see rapid growth due to rising diabetes and CVD rates, while Japan prioritizes precision interventions.
Rest of the World: Brazil enhances vascular care, and the Middle East invests in advanced medical technologies.

Application Analysis
Hospitals: Expected growth of 6.2%-10.2%, driven by complex cardiovascular procedures. Trends focus on IVL and imaging integration.
Ambulatory Surgery Centers: Projected growth of 5.8%-9.8%, linked to outpatient interventions. Developments emphasize portable devices.
Cardiac Catheterization Labs: Anticipated growth of 6.0%-10.0%, tied to specialized procedures. Advances prioritize AI-assisted navigation.
Others: Expected growth of 5.6%-9.6%, covering clinics. Trends lean toward cost-effective solutions.

Type Analysis
Atherectomy Devices: Expected growth of 6.3%-10.3%, driven by plaque removal precision. Trends highlight laser and orbital technologies.
Thrombectomy Devices: Projected growth of 6.1%-10.1%, linked to stroke and DVT treatment. Innovations focus on aspiration efficiency.
Chronic Total Occlusion Devices: Anticipated growth of 5.9%-9.9%, used in complex cases. Advances include specialized guidewires.
Embolic Protection Devices: Expected growth of 5.7%-9.7%, driven by procedural safety. Trends emphasize filter designs.

Key Market Players
Leading companies include Boston Scientific Corporation, known for Rotapro; Medtronic, offering advanced IVL; Abbott, focusing on imaging integration; BD, supporting vascular access; Philips, innovating with IVUS; Stryker, targeting thrombectomy; AngioDynamics, emphasizing peripheral interventions; Terumo Corporation, advancing catheter systems; Penumbra, known for Lightning systems; REX MEDICAL, offering vascular solutions; ARGON MEDICAL, specializing in embolic protection; and Soundbite Medical Solutions, focusing on novel lithotripsy.

Porter's Five Forces Analysis
Threat of New Entrants: Moderate, due to high regulatory and R&D barriers, though innovative startups can disrupt.
Threat of Substitutes: Low, as minimally invasive devices are preferred for CVD treatment.
Bargaining Power of Buyers: Moderate, with hospitals seeking advanced, cost-effective devices, but clinical needs limit options.
Bargaining Power of Suppliers: Low, given multiple component suppliers.
Competitive Rivalry: High, with firms competing on imaging integration, automation, and procedural efficiency.

Market Opportunities and Challenges
Opportunities:
High CVD prevalence, with 17.9 million deaths annually, drives demand.
The aging population, projected at 2.1 billion by 2050, boosts intervention needs.
Minimally invasive trends, with IVL and laser atherectomy, reduce recovery times by 40%.
Technological advancements, like Penumbra’s Lightning and Philips’ IVUS, improve procedural success rates.
Challenges:
High device costs limit adoption in low-income regions.
Regulatory delays for AI and novel technologies slow market entry.
Shortages of interventional cardiologists in rural areas constrain growth, as does the need for skilled training in advanced systems.

Market News
In April 2024, Expanse ICE’s ICE Aspiration System received FDA 510(k) clearance, entering the peripheral thrombectomy market.
In 2024, Surmodics, Inc. obtained FDA 510(k) clearance for its Pounce LP Thrombectomy System.
In October 2023, Cardio Flow, Inc. received FDA clearance for its FreedomFlow Orbital Atherectomy Platform.
In March 2023, Penumbra launched the Lightning Bolt 7 arterial thrombectomy system for stroke treatment.
In September 2024, MicroVention, Inc. rebranded to Terumo Neuro, focusing on neurovascular innovation.